Search

Your search keyword '"Anders, Carey K."' showing total 534 results
Start Over Author "Anders, Carey K."
534 results on '"Anders, Carey K."'

1. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities

Author

Kim, Michelle M, Mehta, Minesh P, Smart, DeeDee K, Steeg, Patricia S, Hong, Julie A, Espey, Michael G, Prasanna, Pataje G, Crandon, Laura, Hodgdon, Christine, Kozak, Niki, Armstrong, Terri S, Morikawa, Aki, Willmarth, Nicole, Tanner, Kirk, Boire, Adrienne, Gephart, Melanie Hayden, Margolin, Kim A, Hattangadi-Gluth, Jona, Tawbi, Hussein, Trifiletti, Daniel M, Chung, Caroline, Basu-Roy, Upal, Burns, Robyn, Oliva, Isabella C Glitza, Aizer, Ayal A, Anders, Carey K, Davis, Joanne, Ahluwalia, Manmeet S, Chiang, Veronica, Li, Jing, Kotecha, Rupesh, Formenti, Silvia C, Ellingson, Benjamin M, Gondi, Vinai, Sperduto, Paul W, Barnholtz-Sloan, Jill S, Rodon, Jordi, Lee, Eudocia Q, Khasraw, Mustafa, Yeboa, Debra Nana, Brastianos, Priscilla K, Galanis, Evanthia, Coleman, C Norman, and Ahmed, Mansoor M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Rare Diseases, Clinical Research, Cancer, Brain Disorders, Good Health and Well Being, United States, Humans, Quality of Life, National Cancer Institute (U.S.), Biomedical Research, Consensus, Brain Neoplasms, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient survival, function, and quality of life, mandating a multidimensional approach to clinical care and research. At a virtual National Cancer Institute Workshop in September, 2022, key stakeholders convened to define research priorities to address the crucial areas of unmet need for patients with brain metastases to achieve meaningful advances in patient outcomes. This Policy Review outlines existing knowledge gaps, collaborative opportunities, and specific recommendations regarding consensus priorities and future directions in brain metastases research. Achieving major advances in research will require enhanced coordination between the ongoing efforts of individual organisations and consortia. Importantly, the continual and active engagement of patients and patient advocates will be necessary to ensure that the directionality of all efforts reflects what is most meaningful in the context of patient care.

Published
2023

10. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Rodler, Eve, Sharma, Priyanka, Barlow, William E, Gralow, Julie R, Puhalla, Shannon L, Anders, Carey K, Goldstein, Lori, Tripathy, Debu, Brown-Glaberman, Ursa A, Huynh, Thu-Tam, Szyarto, Christopher S, Godwin, Andrew K, Pathak, Harsh B, Swisher, Elizabeth M, Radke, Marc R, Timms, Kirsten M, Lew, Danika L, Miao, Jieling, Pusztai, Lajos, Hayes, Daniel F, and Hortobagyi, Gabriel N

Published
2023
Full Text
View/download PDF

13. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.

Author

Andre, Fabrice, primary, Hamilton, Erika P., additional, Loi, Sherene, additional, Anders, Carey K., additional, Schmid, Peter, additional, Stroyakovskiy, Daniil, additional, Villanueva, Rafael, additional, Pedrini, Jose Luiz, additional, Doval, Dinesh Chandra, additional, Zurawski, Bogdan, additional, Chen, Shin-Cheh, additional, Boston, Sarice Renee, additional, Konpa, Adam, additional, Pierotti, Barbara, additional, Fabbri, Giulia, additional, and Jhaveri, Komal L., additional

Published
2024
Full Text
View/download PDF

14. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Author

Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, and Cortés, Javier

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Neurosciences, Clinical Trials and Supportive Activities, Breast Cancer, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Brain Neoplasms, Breast Neoplasms, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Polyethylene Glycols, Progression-Free Survival, Topoisomerase I Inhibitors, brain metastases, chemotherapy, etirinotecan pegol, metastatic breast cancer, NKTR-102, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Phase III BEACON trial, this ongoing randomized, Phase III trial compares etirinotecan pegol to drugs commonly used for advanced breast cancer in patients with stable, treated breast cancer brain metastases who have been previously treated with an anthracycline, taxane and capecitabine. The primary end point is overall survival. Secondary end points include objective response rate, progression-free survival and time to CNS disease progression or recurrence in patients with/without CNS lesions present at study entry. Trial registration number: NCT02915744.

Published
2019

18. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022

Author

Freedman, Rachel A., Gelman, Rebecca S., Agar, Nathalie Y.R., Santagata, Sandro, Randall, Elizabeth C., Gimenez-Cassina Lopez, Begoña, Connolly, Roisin M., Dunn, Ian F., Van Poznak, Catherine H., Anders, Carey K., Melisko, Michelle E., Silvestri, Kelly, Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Moy, Beverly, Blackwell, Kimberly L., Puhalla, Shannon L., Ibrahim, Nuhad, Moynihan, Timothy J., Nangia, Julie, Tung, Nadine, Burns, Robyn, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., and Lin, Nancy U.

Published
2020
Full Text
View/download PDF

19. Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer.

Author

Thomas, Alexandra, Broderick, Amanda, and Anders, Carey K.

Subjects
BREAST tumors, ANTINEOPLASTIC agents, MONOCLONAL antibodies, COMBINED modality therapy, EPIDERMAL growth factor receptors, CELL receptors
Abstract

The article comments on a study by F. J. Esteva and E. Katz on the use of neoadjuvant method to the management of patients with human epidermal growth factor receptor-2. Topics mentioned include the application of pathologic complete response as a surrogate marker for survival, the role of taxanes as a key chemotherapy for breast cancer and the need to optimize therapy to address the risk of central nervous system recurrence.

Published
2024
Full Text
View/download PDF

22. Breast Cancer Before 40

Author

Anders, Carey K., Johnson, Rebecca, Litton, Jennifer, Ruddy, Kathryn J., Bleyer, Archie, Reaman, Gregory H., Series editor, Smith, Franklin O., Series editor, Bleyer, Archie, editor, Barr, Ronald, editor, Ries, Lynn, editor, Whelan, Jeremy, editor, and Ferrari, Andrea, editor

Published
2017
Full Text
View/download PDF

25. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors

Author

Vincent, Benjamin G., primary, File, Danielle M., additional, McKinnon, Karen P., additional, Moore, Dominic T., additional, Frelinger, Jeffrey A., additional, Collins, Edward J., additional, Ibrahim, Joseph G., additional, Bixby, Lisa, additional, Reisdorf, Shannon, additional, Laurie, Sonia J., additional, Park, Yara A., additional, Anders, Carey K., additional, Collichio, Frances A., additional, Muss, Hyman B., additional, Carey, Lisa A., additional, van Deventer, Hendrik W., additional, Dees, E. Claire, additional, and Serody, Jonathan S., additional

Published
2023
Full Text
View/download PDF

28. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

Author

Siegel, Marni B., He, Xiaping, Hoadley, Katherine A., Hoyle, Alan, Pearce, Julia B., Garrett, Amy L., Kumar, Sunil, Moylan, Vincent J., Brady, Claudia M., Van Swearingen, Amanda E.D., Marron, David, Gupta, Gaorav P., Thorne, Leigh B., Kieran, Niamh, Livasy, Chad, Mardis, Elaine R., Parker, Joel S., Chen, Mengjie, Anders, Carey K., Carey, Lisa A., and Perou, Charles M.

Subjects
Cancer genetics -- Research, DNA sequencing -- Usage -- Health aspects, RNA sequencing -- Usage -- Health aspects, Breast cancer -- Genetic aspects -- Development and progression, Cancer metastasis -- Genetic aspects -- Development and progression, Health care industry
Abstract

Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate the underlying mechanisms that cause breast cancer metastasis. To address this issue, we performed DNA exome and RNA sequencing of matched primary tumors and multiple metastases from 16 patients, totaling 83 distinct specimens. We identified tumor-specific drivers by integrating known protein-protein network information with RNA expression and somatic DNA alterations and found that genetic drivers were predominantly established in the primary tumor and maintained through metastatic spreading. In addition, our analyses revealed that most genetic drivers were DNA copy number changes, the TP53 mutation was a recurrent founding mutation regardless of subtype, and that multiclonal seeding of metastases was frequent and occurred in multiple subtypes. Genetic drivers unique to metastasis were identified as somatic mutations in the estrogen and androgen receptor genes. These results highlight the complexity of metastatic spreading, be it monoclonal or multiclonal, and suggest that most metastatic drivers are established in the primary tumor, despite the substantial heterogeneity seen in the metastases., Introduction Breast cancer remains the second leading cause of cancer-related death in women in the United States and is typically caused by metastasis. Significant genetic heterogeneity exists both within a [...]

Published
2018
Full Text
View/download PDF

29. Data from Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Author

Jenkins, Sarah, primary, Zhang, Wei, primary, Steinberg, Seth M., primary, Nousome, Darryl, primary, Houston, Nicole, primary, Wu, Xiaolin, primary, Armstrong, Terri S., primary, Burton, Eric, primary, Smart, Dee Dee, primary, Shah, Ritu, primary, Peer, Cody J., primary, Mozarsky, Brett, primary, Arisa, Oluwatobi, primary, Figg, William D., primary, Mendoza, Tito R., primary, Vera, Elizabeth, primary, Brastianos, Priscilla, primary, Carter, Scott, primary, Gilbert, Mark R., primary, Anders, Carey K., primary, Connolly, Roisín M., primary, Tweed, Carol, primary, Smith, Karen L., primary, Khan, Imran, primary, Lipkowitz, Stanley, primary, Steeg, Patricia S., primary, and Zimmer, Alexandra S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data 1 from Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Author

Jenkins, Sarah, primary, Zhang, Wei, primary, Steinberg, Seth M., primary, Nousome, Darryl, primary, Houston, Nicole, primary, Wu, Xiaolin, primary, Armstrong, Terri S., primary, Burton, Eric, primary, Smart, Dee Dee, primary, Shah, Ritu, primary, Peer, Cody J., primary, Mozarsky, Brett, primary, Arisa, Oluwatobi, primary, Figg, William D., primary, Mendoza, Tito R., primary, Vera, Elizabeth, primary, Brastianos, Priscilla, primary, Carter, Scott, primary, Gilbert, Mark R., primary, Anders, Carey K., primary, Connolly, Roisín M., primary, Tweed, Carol, primary, Smith, Karen L., primary, Khan, Imran, primary, Lipkowitz, Stanley, primary, Steeg, Patricia S., primary, and Zimmer, Alexandra S., primary

Published
2023
Full Text
View/download PDF

31. Figure S1 from Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Author

Jenkins, Sarah, primary, Zhang, Wei, primary, Steinberg, Seth M., primary, Nousome, Darryl, primary, Houston, Nicole, primary, Wu, Xiaolin, primary, Armstrong, Terri S., primary, Burton, Eric, primary, Smart, Dee Dee, primary, Shah, Ritu, primary, Peer, Cody J., primary, Mozarsky, Brett, primary, Arisa, Oluwatobi, primary, Figg, William D., primary, Mendoza, Tito R., primary, Vera, Elizabeth, primary, Brastianos, Priscilla, primary, Carter, Scott, primary, Gilbert, Mark R., primary, Anders, Carey K., primary, Connolly, Roisín M., primary, Tweed, Carol, primary, Smith, Karen L., primary, Khan, Imran, primary, Lipkowitz, Stanley, primary, Steeg, Patricia S., primary, and Zimmer, Alexandra S., primary

Published
2023
Full Text
View/download PDF

32. Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

33. Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

34. Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

35. Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non–Small Cell Lung Cancer and Triple-Negative Breast Cancer

Author

Mercer-Smith, Alison R., primary, Jiang, Wulin, primary, Bago, Juli R., primary, Valdivia, Alain, primary, Thang, Morrent, primary, Woodell, Alex S., primary, Montgomery, Stephanie A., primary, Sheets, Kevin T., primary, Anders, Carey K., primary, and Hingtgen, Shawn D., primary

Published
2023
Full Text
View/download PDF

37. Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figures 1 - 5, Tables 1 - 4 from αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

Author

Malin, Dmitry, primary, Strekalova, Elena, primary, Petrovic, Vladimir, primary, Deal, Allison M., primary, Al Ahmad, Abraham, primary, Adamo, Barbara, primary, Miller, C. Ryan, primary, Ugolkov, Andrey, primary, Livasy, Chad, primary, Fritchie, Karen, primary, Hamilton, Erika, primary, Blackwell, Kimberly, primary, Geradts, Joseph, primary, Ewend, Matt, primary, Carey, Lisa, primary, Shusta, Eric V., primary, Anders, Carey K., primary, and Cryns, Vincent L., primary

Published
2023
Full Text
View/download PDF

39. Supplemental Table 1 from Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium

Author

Chollet-Hinton, Lynn, primary, Olshan, Andrew F., primary, Nichols, Hazel B., primary, Anders, Carey K., primary, Lund, Jennifer L., primary, Allott, Emma H., primary, Bethea, Traci N., primary, Hong, Chi-Chen, primary, Cohen, Stephanie M., primary, Khoury, Thaer, primary, Zirpoli, Gary R., primary, Borges, Virginia F., primary, Rosenberg, Lynn A., primary, Bandera, Elisa V., primary, Ambrosone, Christine B., primary, Palmer, Julie R., primary, and Troester, Melissa A., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 2 from Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Author

Valiente, Manuel, primary, Van Swearingen, Amanda E.D., primary, Anders, Carey K., primary, Bairoch, Amos, primary, Boire, Adrienne, primary, Bos, Paula D., primary, Cittelly, Diana M., primary, Erez, Neta, primary, Ferraro, Gino B., primary, Fukumura, Dai, primary, Gril, Brunilde, primary, Herlyn, Meenhard, primary, Holmen, Sheri L., primary, Jain, Rakesh K., primary, Joyce, Johanna A., primary, Lorger, Mihaela, primary, Massague, Joan, primary, Neman, Josh, primary, Sibson, Nicola R., primary, Steeg, Patricia S., primary, Thorsen, Frits, primary, Young, Leonie S., primary, Varešlija, Damir, primary, Vultur, Adina, primary, Weis-Garcia, Frances, primary, and Winkler, Frank, primary

Published
2023
Full Text
View/download PDF

41. Figure S1 from Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Author

Valiente, Manuel, primary, Van Swearingen, Amanda E.D., primary, Anders, Carey K., primary, Bairoch, Amos, primary, Boire, Adrienne, primary, Bos, Paula D., primary, Cittelly, Diana M., primary, Erez, Neta, primary, Ferraro, Gino B., primary, Fukumura, Dai, primary, Gril, Brunilde, primary, Herlyn, Meenhard, primary, Holmen, Sheri L., primary, Jain, Rakesh K., primary, Joyce, Johanna A., primary, Lorger, Mihaela, primary, Massague, Joan, primary, Neman, Josh, primary, Sibson, Nicola R., primary, Steeg, Patricia S., primary, Thorsen, Frits, primary, Young, Leonie S., primary, Varešlija, Damir, primary, Vultur, Adina, primary, Weis-Garcia, Frances, primary, and Winkler, Frank, primary

Published
2023
Full Text
View/download PDF

42. Data from Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Author

Valiente, Manuel, primary, Van Swearingen, Amanda E.D., primary, Anders, Carey K., primary, Bairoch, Amos, primary, Boire, Adrienne, primary, Bos, Paula D., primary, Cittelly, Diana M., primary, Erez, Neta, primary, Ferraro, Gino B., primary, Fukumura, Dai, primary, Gril, Brunilde, primary, Herlyn, Meenhard, primary, Holmen, Sheri L., primary, Jain, Rakesh K., primary, Joyce, Johanna A., primary, Lorger, Mihaela, primary, Massague, Joan, primary, Neman, Josh, primary, Sibson, Nicola R., primary, Steeg, Patricia S., primary, Thorsen, Frits, primary, Young, Leonie S., primary, Varešlija, Damir, primary, Vultur, Adina, primary, Weis-Garcia, Frances, primary, and Winkler, Frank, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table S2 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Author

Tolaney, Sara M., primary, Sahebjam, Solmaz, primary, Le Rhun, Emilie, primary, Bachelot, Thomas, primary, Kabos, Peter, primary, Awada, Ahmad, primary, Yardley, Denise, primary, Chan, Arlene, primary, Conte, Pierfranco, primary, Diéras, Véronique, primary, Lin, Nancy U., primary, Bear, Melissa, primary, Chapman, Sonya C., primary, Yang, Zhengyu, primary, Chen, Yanyun, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 1 from Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

Author

Valiente, Manuel, primary, Van Swearingen, Amanda E.D., primary, Anders, Carey K., primary, Bairoch, Amos, primary, Boire, Adrienne, primary, Bos, Paula D., primary, Cittelly, Diana M., primary, Erez, Neta, primary, Ferraro, Gino B., primary, Fukumura, Dai, primary, Gril, Brunilde, primary, Herlyn, Meenhard, primary, Holmen, Sheri L., primary, Jain, Rakesh K., primary, Joyce, Johanna A., primary, Lorger, Mihaela, primary, Massague, Joan, primary, Neman, Josh, primary, Sibson, Nicola R., primary, Steeg, Patricia S., primary, Thorsen, Frits, primary, Young, Leonie S., primary, Varešlija, Damir, primary, Vultur, Adina, primary, Weis-Garcia, Frances, primary, and Winkler, Frank, primary

Published
2023
Full Text
View/download PDF

45. The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice

Author

Broom, Alex, primary, Williams Veazey, Leah, additional, Kenny, Katherine, additional, Harper, Imogen, additional, Peterie, Michelle, additional, Page, Alexander, additional, Cort, Nicole, additional, Durling, Jennifer, additional, Lipp, Eric S., additional, Tan, Aaron C., additional, Walsh, Kyle M., additional, Hanks, Brent A., additional, Johnson, Margaret, additional, Van Swearingen, Amanda E.D., additional, Anders, Carey K., additional, Ashley, David M., additional, and Khasraw, Mustafa, additional

Published
2023
Full Text
View/download PDF

46. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

Author

Zhu, Li, Narloch, Jessica L., Onkar, Sayali, Joy, Marion, Broadwater, Gloria, Luedke, Catherine, Hall, Allison, Kim, Rim, Pogue-Geile, Katherine, Sammons, Sarah, Nayyar, Naema, Chukwueke, Ugonma, Brastianos, Priscilla K., Anders, Carey K., Soloff, Adam C., Vignali, Dario A. A., Tseng, George C., Emens, Leisha A., Lucas, Peter C., Blackwell, Kimberly L., Oesterreich, Steffi, and Lee, Adrian V.

Published
2019
Full Text
View/download PDF

47. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Author

Jenkins, Sarah, primary, Zhang, Wei, additional, Steinberg, Seth M., additional, Nousome, Darryl, additional, Houston, Nicole, additional, Wu, Xiaolin, additional, Armstrong, Terri S., additional, Burton, Eric, additional, Smart, DeeDee, additional, Shah, Ritu, additional, Peer, Cody J., additional, Mozarsky, Brett, additional, Arisa, Oluwatobi, additional, Figg, William D., additional, Mendoza, Tito R., additional, Vera, Elizabeth, additional, Brastianos, Priscilla, additional, Carter, Scott, additional, Gilbert, Mark R., additional, Anders, Carey K., additional, Connolly, Roisin M., additional, Tweed, Carol, additional, Smith, Karen L., additional, Khan, Imran, additional, Lipkowitz, Stanley, additional, Steeg, Patricia S., additional, and Zimmer, Alexandra S., additional

Published
2023
Full Text
View/download PDF

49. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer

Author

Taylor, Nicholas A., Vick, Sarah C., Iglesia, Michael D., Brickey, W. June, Midkiff, Bentley R., McKinnon, Karen P., Reisdorf, Shannon, Anders, Carey K., Carey, Lisa A., Parker, Joel S., Perou, Charles M., Vincent, Benjamin G., and Serody, Jonathan S.

Subjects
Breast cancer -- Genetic aspects, Gene expression -- Health aspects, T cells -- Genetic aspects -- Health aspects, Health care industry
Abstract

Claudin-low breast cancer is an aggressive subtype that confers poor prognosis and is found largely within the clinical triple-negative group of breast cancer patients. Here, we have shown that intrinsic and immune cell gene signatures distinguish the claudin-low subtype clinically as well as in mouse models of other breast cancer subtypes. Despite adaptive immune cell infiltration in claudin-low tumors, treatment with immune checkpoint inhibitory antibodies against cytotoxic T lymphocyteassociated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1) were ineffective in controlling tumor growth. [CD4.sup.+][FoxP3.sup.+] Tregs represented a large proportion of the tumor -infiltrating lymphocytes (TILs) in claudin-low tumors, and Tregs isolated from tumor-bearing mice were able to suppress effector T cell responses. Tregs in the tumor microenvironment highly expressed PD-1 and were recruited partly through tumor generation of the chemokine CXCL12. Antitumor efficacy required stringent Treg depletion combined with checkpoint inhibition; delays in tumor growth were not observed using therapies that modestly diminished the number of Tregs in the tumor microenvironment. This study provides evidence that the recruitment of Tregs to the tumor microenvironment inhibits an effective antitumor immune response and highlights early Treg recruitment as a possible mechanism for the lack of response to immune checkpoint blockade antibodies in specific subtypes of cancer that are heavily infiltrated with adaptive immune cells., Introduction Breast cancer is the leading cancer diagnosis and second-leading cause of cancer death for women in the United States (1). Patient prognosis is determined largely by stratification based on [...]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results